Novelion

NVLN-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about NVLN-T

Signal
Opinion
Expert
BUY WEAKNESS
BUY WEAKNESS
August 7, 2009
(Market Call Minute.) Could see it as a Buy but would like it at a cheaper price.
Show full opinionHide full opinion
Novelion (NVLN-T)
August 7, 2009
(Market Call Minute.) Could see it as a Buy but would like it at a cheaper price.
SELL
SELL
October 23, 2007
The future isn't bright. Losing market share with their main product. Suggests tax loss selling.
Show full opinionHide full opinion
Novelion (NVLN-T)
October 23, 2007
The future isn't bright. Losing market share with their main product. Suggests tax loss selling.
DON'T BUY
DON'T BUY
December 22, 2005
Has been a very disappointing stock. Had problems with its major drug because of competition. The problem with the Canadian drug sector is that it tends to be one or two drug dependent.
Show full opinionHide full opinion
Novelion (NVLN-T)
December 22, 2005
Has been a very disappointing stock. Had problems with its major drug because of competition. The problem with the Canadian drug sector is that it tends to be one or two drug dependent.
SELL
SELL
November 11, 2005
The biggest threat to any business is a competing technology or product. That's what the market thinks is happening here.
Show full opinionHide full opinion
Novelion (NVLN-T)
November 11, 2005
The biggest threat to any business is a competing technology or product. That's what the market thinks is happening here.
DON'T BUY
DON'T BUY
September 29, 2005
The drug companys are due for a slow turn around. Had a lot of problems with the FDA. Lots of competition going to happen.
Show full opinionHide full opinion
Novelion (NVLN-T)
September 29, 2005
The drug companys are due for a slow turn around. Had a lot of problems with the FDA. Lots of competition going to happen.
DON'T BUY
DON'T BUY
August 11, 2005
Looks cheap at 10 X earnings. Have a drug that is photo-activated, but competitors have come which has pulled the stock down. Bought a company that had an acne cream, but because of labeling problems, it's another year or two away.
Show full opinionHide full opinion
Novelion (NVLN-T)
August 11, 2005
Looks cheap at 10 X earnings. Have a drug that is photo-activated, but competitors have come which has pulled the stock down. Bought a company that had an acne cream, but because of labeling problems, it's another year or two away.
WAIT
WAIT
June 15, 2005
Likes the company from the standpoint of a product. Thinks they are still way ahead of the competitors, particularily in the eye treatment area. Have expanded their product base which is not bad. Market has been unmerciful to this stock. Hopefully it has hit a bottom, but would wait to see if the stock can work its way through.
Show full opinionHide full opinion
Novelion (NVLN-T)
June 15, 2005
Likes the company from the standpoint of a product. Thinks they are still way ahead of the competitors, particularily in the eye treatment area. Have expanded their product base which is not bad. Market has been unmerciful to this stock. Hopefully it has hit a bottom, but would wait to see if the stock can work its way through.
DON'T BUY
DON'T BUY
June 6, 2005
A one trick pony. Visudine is great, but they haven't really gone beyond this. Getting new competition.
Show full opinionHide full opinion
Novelion (NVLN-T)
June 6, 2005
A one trick pony. Visudine is great, but they haven't really gone beyond this. Getting new competition.
SELL
SELL
May 25, 2005
Their treatment of macular degeneration only treats the latter stage while the competition is going after the initial stage. This company is like a one trick pony. Major competition is coming in.
Show full opinionHide full opinion
Novelion (NVLN-T)
May 25, 2005
Their treatment of macular degeneration only treats the latter stage while the competition is going after the initial stage. This company is like a one trick pony. Major competition is coming in.
DON'T BUY
DON'T BUY
April 11, 2005
This is bottom fishing, bargain hunting on a stock that is below the 200 day moving average. This stock is really base building. The stock is not participating in this bull market, so will possibly sit out the next bear market and you may have to wait for the next bull market which could be 2 years away.
Show full opinionHide full opinion
Novelion (NVLN-T)
April 11, 2005
This is bottom fishing, bargain hunting on a stock that is below the 200 day moving average. This stock is really base building. The stock is not participating in this bull market, so will possibly sit out the next bear market and you may have to wait for the next bull market which could be 2 years away.
DON'T BUY
DON'T BUY
March 10, 2005
Perhaps should sell... recovery could be 6,8,9 months down the road. Could be dead money.
Show full opinionHide full opinion
Novelion (NVLN-T)
March 10, 2005
Perhaps should sell... recovery could be 6,8,9 months down the road. Could be dead money.
WEAK BUY
WEAK BUY
March 9, 2005
Sold his holdings last year and hasn't come back to it yet, but is watching closely. Visudyne now has growing competition. Didn't like the Attrix acquisition and not sure if they will get any growth from it. Has good cash position, assets and core product.
Show full opinionHide full opinion
Novelion (NVLN-T)
March 9, 2005
Sold his holdings last year and hasn't come back to it yet, but is watching closely. Visudyne now has growing competition. Didn't like the Attrix acquisition and not sure if they will get any growth from it. Has good cash position, assets and core product.
DON'T BUY
DON'T BUY
February 15, 2005
You have to wait to see some strength come back in the pharmaceuticals. They were formerly a one drug company, but with their recent acquisition, it makes them a little bit more interesting, but there is still no buying going on.
Show full opinionHide full opinion
Novelion (NVLN-T)
February 15, 2005
You have to wait to see some strength come back in the pharmaceuticals. They were formerly a one drug company, but with their recent acquisition, it makes them a little bit more interesting, but there is still no buying going on.
DON'T BUY
DON'T BUY
February 14, 2005
Visudyne has done really well but competition is coming from Pfizer. Will lose a little bit of market share for awhile and growth will slow down. In the end they may win the battle, but in the short term it will be difficult. Not happy with the recent merger with Atrix Laboritories. Felt they had a weak pipeline.
Show full opinionHide full opinion
Novelion (NVLN-T)
February 14, 2005
Visudyne has done really well but competition is coming from Pfizer. Will lose a little bit of market share for awhile and growth will slow down. In the end they may win the battle, but in the short term it will be difficult. Not happy with the recent merger with Atrix Laboritories. Felt they had a weak pipeline.
WAIT
WAIT
February 1, 2005
Because of the acquisition they just did, would like to see a couple of quarters of results out of the new drugs that are in that acquisition. Has seen some weakness with a 10/15% decline in sales.
Show full opinionHide full opinion
Novelion (NVLN-T)
February 1, 2005
Because of the acquisition they just did, would like to see a couple of quarters of results out of the new drugs that are in that acquisition. Has seen some weakness with a 10/15% decline in sales.
Showing 1 to 15 of 190 entries